Zydus Insists Mitsubishi Doesn't Deserve Diabetes Patents

Law360 (November 25, 2020, 9:20 PM EST) -- Zydus Pharmaceuticals punctuated the six-day trial in its bid to bring generic diabetes drugs to market by filing a 100-page, post-trial brief doubling down on its claim that Mitsubishi Tanabe Pharma Corp. is engaging in "gamesmanship" to extend the life of one of three patents Zydus is accused of infringing.

Mitsubishi lodged a suit in July 2017 seeking to shoot down Zydus' abbreviated new drug application filed with the U.S. Food and Drug Administration for generic versions of the diabetes drugs Invokana and Invokamet. It alleged that the generics maker's bid infringes U.S. Patent No. 7,943,788 issued in May 2011.

On Tuesday, New Jersey-based Zydus Pharmaceuticals...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!